“In the first Phase 3 randomised clinical trial for a KRASG12C inhibitor, oral sotorasib demonstrated superior progression-free survival and an objective response rate compared to standard of care intravenous docetaxel, and had a more favourable safety profile,” said study first author Melissa L Johnson, Sarah Cannon Research Institute at Tennessee Oncology, Nashville, USA.
“This represents a major advance for the treatment of patients with KRAS G12C- mutated non-small cell lung cancer and reinforces the importance of NGS testing to inform treatment decisions for patients with NSCLC.”
“The CodeBreak 200 is the first randomised phase 3 trial, evaluating sotorasib, a selective KRAS G12C inhibitor, in pretreated patients with NSCLC (after prior platinum-based chemotherapy and a immune checkpoint inhibitor). Sotorasib, already received FDA and EMA approval in the same setting based on ORR of the Phase 1/2 CodeBreaK 100 single-arm clinical trial, but a comparative evaluation was highly expected to improve the understanding of this molecular-driven disease and move forward the approval in those countries where sotorasib is not yet reimbursed,” said Antonio Passaro, IEO-Istituto Europeo di Oncologia, Milan, Italy, not involved in the study.
Analysing the results, Passaro added: “As expected, the results confirmed that sotorasib met its primary endpoint improving PFS versus docetaxel while the long-awaited OS was not statistically significant, though the study was not powered for OS and crossover was permitted following disease progression. To date, these results confirm sotorasib as second-line therapy for patients with NSCLC harbouring KRAS G12C mutations and, that further improvements are highly required for this specific molecular-driven patient population, where different kinds of combinations are under evaluation to overcome resistance and improve the modest efficacy of monotherapy.”
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.